Navigation Links
New technology represents next-generation tool for detecting substandard and counterfeit medicines
Date:7/26/2012

Rockville, Md., July 26, 2012 A new platform for detecting substandard and counterfeit medicines using microfluidics has been recognized with a grant from Saving Lives at Birth's "Grand Challenge through Development." Dubbed PharmaCheck, the technology is a portable, field-based tool for assessing the quality of medicines in developing countries with increased accuracy, sensitivity and reliability.

Through the Challenge, the U.S. Agency for International Development (USAID), Bill & Melinda Gates Foundation, Grand Challenges Canada and the U.K. Department for International Development sought groundbreaking prevention and treatment approaches for pregnant women and newborns in poor, hard-to-reach communities in developing countries. Substandard and counterfeit medicines for diseases including malaria, tuberculosis and HIV/AIDS pose a dire public health threat to patients in developing countries, in particular children and pregnant women. Such medicines can exacerbate the course of these diseases, even leading to death, as well as contribute to the growth of drug-resistant disease parasitesthreatening the viability of treatments for patients worldwide.

Developed by Boston University in collaboration with the Promoting the Quality of Medicines (PQM) program, which is supported by USAID and implemented by the U.S. Pharmacopeial Convention (USP), PharmaCheck has reached the proof of concept stagedemonstrating a quantitation linear relationship for analysis of an antimalarial medicine of interest on a microfluidic chip. The technology addresses shortcomings of current field-based, portable quality control laboratories currently in use throughout the developing worldincluding the inability to precisely and accurately measure the percentage of the active pharmaceutical ingredient or other important quality attributes of medicines. These are key to determining whether a medicine is of poor quality or not. Furthermore, the technology is expected to greatly reduce the need for confirmation of field-tested results at fully equipped quality control laboratories.

"This technology promises to be groundbreaking in the fight against substandard and counterfeit medicines," said Mr. Anthony Boni, Pharmaceutical Management Specialist for USAID's Global Health Bureau, Office of Health, Infectious Diseases and Nutrition/Health Systems Division. "Inexpensive, easy-to-use and effective, we expect that PharmaCheck will represent a paradigm shift in combating the scourge of poor-quality medicines. One of the most exciting elements is the ability to potentially deploy this technology at point-of-use, with an ultimate vision of healthcare facilities, clinics and hospitals using the technology to verify the quality of the medicines they receive."

"This technology is an important breakthrough as we strive to help ensure the quality, safety and efficacy of medicines essential to treating patients suffering from malaria, tuberculosis and HIV/AIDS in developing countries around the world," said Dr. Patrick Lukulay, Vice President of Global Health Impact Programs for USP and Director of the PQM Program. "This will be a very powerful tool with broad application and impact. We are very pleased to be partnering with Boston University in advancing this technology."

With this new grant, Boston University, led by Dr. Muhammad Zaman, will be able to accelerate development of PharmaCheck and the deployment of a finished product.


'/>"/>
Contact: Theresa Laranang-Mutlu
trl@usp.org
301-816-8167
US Pharmacopeia
Source:Eurekalert

Related medicine news :

1. WPI to host international workshop focused on technology solutions for first responders
2. New targeting technology improves outcomes for patients with atrial fibrillation
3. New technology improves heart rhythm treatment
4. Researchers to use novel metabolomics technology for COPD
5. University of Minnesota licenses Clinical Decision Support technology
6. Newer technology to control blood sugar works better than conventional methods
7. 3M™ Gripping Material Technology – Giving Golfers a Competitive Edge
8. IVR Technology Group Named Platimum VAR by TSYS
9. FDA Approves SonixGPS Needle Guidance Technology for Vascular Access Procedures
10. Miami Children’s Hospital Performs First Nerve Repair Surgery Using Avance® Nerve Graft Technology
11. Swanson Health Products Introduces a New Alkalizing Drink Mix, Swanson® pH Balance Alka-Tone with Alka-Plex™ Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... , ... December 03, 2016 , ... While James Earl ... serving as host for in a show called "Front Page". One of the forthcoming ... years, breast cancer rates have plummeted in large part due to early detection. Like ...
(Date:12/4/2016)... ... December 04, 2016 , ... Patients who wish to ... advantage of a cosmetic procedure known as Carbon Dioxide (C02) Fractional Laser ... of age spots, fine lines, uneven coloration, wrinkles, scarring, skin laxity or ...
(Date:12/2/2016)... ... December 02, 2016 , ... Lori G. Cohen and ... will speak at the American Conference Institute’s 21st Drug & Medical Device Litigation ... Lead Sponsor of the conference. , Cohen, who chairs the firm’s Pharmaceutical, Medical Device ...
(Date:12/2/2016)... ... December 02, 2016 , ... More than 100 business, civic, ... to attend the UNCF Dothan-Wiregrass Mayor’s Luncheon Dec. 9, 2016. This inaugural event, ... and operating support to UNCF-member institutions, including Miles College, Oakwood University, Tuskegee University, ...
(Date:12/2/2016)... ... , ... The annual time frame to change Medicare health and prescription drug ... 7th. Currently-enrolled Medicare beneficiaries who are looking to switch from their current plan to ... make changes during this period order for their new policy to go into effect ...
Breaking Medicine News(10 mins):
(Date:12/4/2016)... 2016  Results from the Phase II SUSTAIN study ... reduced the median annual rate of sickle cell-related pain ... 2.98, p=0.010) in patients with or without hydroxyurea therapy ... being featured in the official press briefing at the ... Meeting and presented during the Plenary Scientific Session tomorrow ...
(Date:12/2/2016)... December 2, 2016 - bioLytical lanza el INSTI HIV ... la OMS     Continue Reading ... ... , , bioLytical ... anunciado hoy que está expandiendo el lanzamiento de su INSTI HIV Self Test ...
(Date:12/2/2016)... December 2, 2016 According to the ... Market Study on Automated Endoscope Reprocessors: Single Basin Automated Endoscope ... 8.6% Between 2016 and 2024 " the global automated endoscope reprocessors market was ... to expand at a CAGR of 7.2% during an eight-year ... 1,367.6 Mn by 2024. ...
Breaking Medicine Technology: